Figure Technology Solutions, Inc. Class A Common Stock FIGR

At a glance

One-line thesis. Figure is the rare crypto-adjacent company with real GAAP profits — a blockchain-native consumer-finance marketplace (HELOC origination plus capital-markets takeout on its own rails) that grew revenue +64% in FY25 to $457M with a 36% operating margin, and the street sees +71% more in FY26 — but it IPO'd only in September 2025, has already halved from its $73.91 high, shows deeply negative TTM operating cash flow (lender working-capital mechanics), gets street-modeled deceleration to +16% by FY28E, and carries exactly one expert voice in our KB. That mix earns a Watch, not a Buy: our $46 base case is +34% above the price, but we want either a cheaper entry (~$28) or a confirming Q2 print before paying up for an eight-month-old public company.

1. What it is

Figure Technology Solutions (Nasdaq: FIGR) builds and operates blockchain-based platforms for consumer finance — origination (led by home-equity lines of credit), trading, and investing in loans and loan-backed instruments on distributed-ledger rails. Founded 2018, headquartered in Reno, NV; ~530 employees; CEO Michael Tannenbaum; founder Mike Cagney remains a director and 10%+ owner (per Form 4 filings in the data). Formerly FT Intermediate, Inc., renamed August 2025; IPO 2025-09-11 on the Nasdaq Global Market, raising ~$667M of primary stock (FY25 cash-flow statement).

Revenue mix: the FMP data file carries no product- or geography-segment tables for FIGR (seg_prod and seg_geo are empty) — an honest gap. What the KB's single voice describes (see §2) is a two-sided model: originate loans as the largest non-bank originator in its niche, then sell them through Figure's own blockchain marketplace, with 40%+ of a recent quarter's volume bypassing the balance sheet entirely. We can corroborate the shape of that in the financials (90% TTM gross margin, heavy interest income and expense lines, large warehouse-style short-term debt) but not the segment detail.

2. The expert thesis — why the panel is bullish (traceable)

The Synthos KB holds 5 traceable claims on FIGR from exactly 1 voice — Anthony Pompliano (skill 1.0, forecasting/crypto). That is thin, single-source coverage, and two of the five claims relay founder Mike Cagney, who is talking his own book. All five claims are undated in the KB, so freshness cannot be verified. This note is therefore substantially fundamentals-driven, with the Pompliano thesis as color rather than conviction:

• The disintermediation thesis (the core claim). "Figure controls both origination and capital-markets takeout on native blockchain rails; largest non-bank originator, disintermediating itself into a pure marketplace operator" (Anthony Pompliano, doc anthony_pompliano-n9DB2xap9OQ, conviction 85, undated). The relayed founder version: the marketplace model "disintermediates itself, expanding margins" (Mike Cagney via Pompliano, same doc, conviction 85).
• The margin proof-point. "EBITDA margin rose from 31% to 37% (Q1) to 47% (Q2) as over 40% of Q2 volume flowed directly through its blockchain marketplace" (Pompliano, conviction 70; echoed via Cagney at conviction 80). Honest weighting: these are company-sourced, presumably adjusted figures, undated, and the relayed versions come from the founder — treat as directional, not audited.
• The product-optionality claim. Figure's "yields" product is "a face-amount-certificate security — freely transferable peer-to-peer, treasury-backed, paying ~4% (SOFR minus 35bps); a transferable money-market fund" (Pompliano, conviction 70) — i.e., a tokenized-securities franchise beyond lending.

Honest composite note. One bullish crypto-native voice, no bearish or even neutral counterweight, no dates, and two claims that are effectively management-sourced. Breadth 1 is the weakest expert base in the coverage universe — so the bear case in §3 is built entirely from the fundamentals and the price action, and conviction is scored Low by construction.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision.

Synthos fair value = the base case, ~$46 (+34%), full range $24–$72. Note we sit well below the street's $62.75 consensus: with 3–5 analysts, a single FY28 estimate, and an undated single-voice expert base, we will not underwrite the street's ~50× FY27 multiple on an eight-month trading history. A +34% base-case gap would normally argue for a Buy — the Watch verdict is a deliberate conviction discount, and the trigger is explicit: ~$28 or a clean Q2 2026 print. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders from exponentials (accelerating, multi-baggers-from-here). FIGR is a candidate exponential that currently fails the acceleration test:

• Forward growth: street revenue $457M (FY25 actual) → $782M FY26E (+71%) → $961M FY27E (+23%) → $1,112M FY28E (+16%). EPS $0.44 diluted FY25 → $1.01 FY26E → $1.26 FY27E → $1.55 FY28E — a ~24% EPS CAGR FY26E→FY28E after the FY26 step-change.
• Acceleration (the 2nd derivative) is negative on street numbers: +64% → +71% → +23% → +16%. The FY26 surge is real (Q1-26 revenue +201% YoY), but analysts model a hard fade after it. Caveat in both directions: FY27 rests on 5 revenue estimates, FY28 on one — the fade could be analyst laziness on an under-covered new listing, or it could be right.
• Room to run: at $6.3B, against consumer-credit origination plus tokenized capital markets, size is no constraint — a 3–5× outcome is arithmetically easy if growth re-accelerates. This is what keeps the score at 6 rather than 4.
• Reinvestment model: capex is negligible (~0.9% of revenue TTM) — the "reinvestment" is balance-sheet loan warehousing, which consumes cash flow (TTM FCF/share −$17.26) and depends on funding markets. An asset-light software story on the income statement; a lender on the cash-flow statement.

Exponential Potential: 6/10. Huge TAM, small cap, real profits — but until the growth stops decelerating on actual prints, it is a potential exponential, not a demonstrated one. Watch the Q2 (2026-08-10) revenue print against the ~$202M street bar.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $457.2M, +63.7% (FY24 $279.3M, +67.4% on FY23 $166.9M). TTM revenue ≈ $620M (last four reported quarters).
• Quarterly trajectory (lumpy, but steeply up YoY): Q1-25 $55.4M → Q2-25 $95.1M → Q3-25 $134.9M → Q4-25 $223.2M → Q1-26 $167.0M (+201% YoY, −25% QoQ). The Q4→Q1 step-down and the Q4 G&A spike ($82.5M) say quarterly seasonality/lumpiness is real — judge this name YoY, not sequentially.
• Margins: gross 90.0% TTM (FY25 78.7%), EBITDA margin 35.2% TTM, operating margin 32.9% TTM (FY25 36.3%, vs FY24's 3.3% and a FY23 operating loss) — a real profitability inflection through 2025.
• Earnings quality — read very carefully. FY25 GAAP net income $133.9M / diluted EPS $0.44; Q1-26 net income $44.9M / diluted EPS $0.18. But this is a lender: TTM operating cash flow is deeply negative (−$17.23/share; income-quality −20.8) because loan originations flow through working capital ($6.56B FY25 working-capital swing). The FY25 tax line is a benefit (−$20.6M) and Q1-26 likewise (−$6.9M) — flattering net income; pre-tax is the cleaner line (FY25 $113.7M). Also note Q3-25's $89.6M net income includes a $31.5M tax benefit and a $71.8M net-income deduction line — one-offs around the IPO quarter.
• Cash flow: FY25 operating CF +$62.6M, capex ~$0, FCF +$62.6M — positive at the annual level, unlike the TTM window. FY24 was −$152.6M FCF. Funding: FY25 raised $667M in the IPO and $251M net new debt.
• Balance sheet: cash + short-term investments $1.36B, total debt $946.7M (of which $712M short-term — warehouse-style facilities typical of an originator), net debt −$320M (net cash). Equity $1.23B; tangible book = book at $5.95/share (zero goodwill/intangibles — refreshing). Current ratio 2.1×; interest coverage 3.7× TTM.
• Dilution watch: FY25 basic shares 228.9M vs diluted 283.6M — a 24% overhang; FY25 stock-comp $62.4M ≈ 14% of revenue.

6. Valuation — priced in or room?

On trailing numbers FIGR is expensive but not absurd for the growth: 41.6× trailing EPS, 28.1× EV/EBITDA, 9.9× EV/sales, 5.8× book. FMP's letter rating is B− (overall 2/5; DCF, P/E and P/B each score 1/5 — the quant model dislikes the price). The forward curve does the usual fast-grower compression: ~34× FY26E ($1.01) → ~27× FY27E ($1.26) → ~22× FY28E ($1.55) — reasonable multiples if the estimates hold, on estimates held by only 3–5 analysts (FY28: one). The street's $62.75 consensus target (+82%) implies ~50× FY27E — we won't underwrite that on this maturity; our $46 base = ~36× FY27E. The honest framing: the stock has already de-rated by half from its post-IPO $73.91 high, so much froth is gone — but "cheaper than the IPO pop" is not the same as cheap, and a negative-OCF, regulation-exposed lender at 10× sales still needs everything in the growth story to be roughly true. Not a value buy; a growth option priced at a growth premium.

7. Technicals (from the tech block)

• Trend: damaged. $34.41 is above the 50-DMA ($33.11) but below the 200-DMA ($38.83), and the 50 sits below the 200 (bearish posture). MACD −0.21 (slightly negative).
• Location: −53.4% off the 52-week high ($73.91) — also the max drawdown from peak — and +36.1% off the 52-week low ($25.28). A broken post-IPO chart attempting a base.
• Momentum: RSI(14) 71 — overbought — on a bounce off the lows, not on strength at highs. Chasing here buys a hot short-term tape inside a downtrend.
• Relative strength (the tell): −0.3% over 3 months vs SPY +14.6% / QQQ +23.6%; −15.7% over 6 months vs SPY +10.2%. 12-month return is n/a — listed under 12 months (IPO 2025-09-11). A clear relative-strength laggard.
• Read: technicals support Watch, not Buy — a −53% drawdown with an overbought bounce below a falling 200-DMA is exactly the setup where patience is paid. Reclaiming and holding the 200-DMA (~$39) would be the technical confirmation; a fade back toward ~$28 would be the value entry.

8. Moat & competitive position

The claimed moat is vertical integration on proprietary rails: Figure both originates (largest non-bank originator in its niche, per the single KB voice) and clears/distributes on its own blockchain marketplace — so scale should compound into better takeout economics, which the 31%→47% EBITDA-margin claim (§2, company-sourced) gestures at. The 90% TTM gross margin and near-zero capex are consistent with a genuine platform. Limits of the moat: switching costs for loan buyers are unproven; incumbent capital-markets plumbing (and better-funded fintechs) can compress the spread; and the "blockchain rails" advantage is partly a regulatory bet — the same novelty that cuts cost invites scrutiny. ROIC of 7.5% says the moat is not yet earning elite returns.

Peer set (FMP-supplied, market cap): a mixed regional-bank/broker bag rather than clean comps — Stifel $11.5B, Marex $4.8B, Sprott $3.1B, First Merchants $2.7B, First Bancorp $2.6B, Beacon Financial $2.5B, Hilltop $2.3B, LendingClub $2.2B (the only real analog), Perella Weinberg $1.1B, Bitfarms $1.3B. The most relevant comparators (SoFi, Coinbase, Rocket, UWM, tokenization plays) are not in the supplied set — a data caveat: judge FIGR against fintech originators and crypto-financial-infrastructure names, not this list. Within the list shown, FIGR carries by far the richest sales multiple — and much the fastest growth.

9. Management, capital allocation & guidance

• Capital allocation: early-stage and sensible so far — the $667M IPO proceeds sit as balance-sheet strength (net cash −$320M), no buybacks, no common dividend (FY25), capex ~nil; capital goes into loan warehousing and platform growth. Nothing to criticize yet, and nothing to grade either — one year of public capital allocation is not a record.
• Insider activity (a genuine yellow flag): CFO Minchung Kgil sold on four separate June dates — 9,117 sh @ $30.06 (6/15), 4,000 sh @ $27.40–$29.01 (6/24, three lots), 4,000 sh @ $30.03 (6/30) — ~17,100 shares total at prices below today's, with ~500k still held. Possibly 10b5-1 diversification post-lockup, but a CFO selling into a −50% drawdown is not what conviction looks like. Founder Mike Cagney and June Ou (directors, 10% owners) received routine stock awards 6/04; no insider buys in the file.
• Guidance: the data file contains no management guidance fields, and the KB has no dated management claims — honestly, we have only the street's Q2 bar (EPS $0.25, rev ~$202M, 2026-08-10). Track record so far: Q2-25 print beat (EPS $0.34 vs $0.16 est), Q4-25 missed badly (EPS $0.06 vs $0.13 est), Q1-26 roughly in line (EPS $0.18 vs $0.19 est, revenue beat $167.0M vs $159.5M est). Two beats, one miss, eight months of history.

10. Catalysts & what to watch

• Next earnings: 2026-08-10 (Q2 2026; Street EPS $0.25, revenue ~$202M). The key lines: YoY origination/revenue growth (does the +71% FY26E path hold?) and any disclosed marketplace-mix / adjusted-EBITDA-margin progression (the §2 thesis's proof metric).
• Marketplace mix: the share of volume bypassing the balance sheet — the entire disintermediation thesis lives or dies on this number continuing to climb.
• Regulatory news on tokenized securities / blockchain lending: the "yields" face-amount-certificate product and on-chain loan trading sit in evolving SEC/CFPB territory — headlines cut both ways and will move a $6.3B name violently.
• Funding markets: warehouse-line cost and capacity ($712M short-term debt) — an originator's growth is hostage to its funding.
• Lockup/insider flow: post-IPO supply and further Form 4 sales, given the CFO's June pattern.
• Estimate breadth: more analysts initiating (currently 3–5) would itself de-risk the multiple.

Thesis tripwires (what would change the call): a Q2 revenue print materially below ~$202M; marketplace mix flat/down; any enforcement action touching Figure's products; warehouse-funding stress; or a second consecutive EPS miss.

11. Key risks

• Regulatory (the dominant risk): blockchain-native lending, on-chain loan trading, and quasi-money-market tokenized securities are exactly where securities and consumer-finance regulators are most active; an adverse action breaks the thesis, not just the quarter.
• Deceleration: the street's own path (+71% → +23% → +16%) says the hypergrowth window closes fast; at 34× FY26E, a growth stall means a multiple crack on top of an estimate cut.
• IPO immaturity: eight months of trading, −53% drawdown already, thin float history, meaningless beta, 3–5-analyst coverage with FY28 on one analyst — price discovery is not finished.
• Lender mechanics: negative TTM operating cash flow, $712M short-term warehouse debt, credit risk on retained loans, and rate sensitivity of HELOC demand and loan-sale economics.
• Cash-flow opacity / earnings quality: working-capital swings in the billions, tax benefits flattering FY25 and Q1-26 net income, IPO-quarter one-offs — GAAP EPS overstates steady-state earnings power by an unknowable amount.
• Dilution & incentives: 24% basic-to-diluted gap, FY25 stock-comp ~14% of revenue, CFO selling in June.
• Evidence thinness: one bullish, undated expert voice (partly relaying the founder) — nothing independent corroborates the qualitative story.

12. Verdict, position sizing & monitoring

Watch. The bull skeleton is real: +64% FY25 revenue growth to $457M with a 36% operating margin, +71% more expected this year, 90% TTM gross margin, net cash, zero goodwill, a $6.3B cap against a huge tokenization TAM, and a street consensus 82% above the price. But every conviction input is weak: an 8-month-old listing already cut in half, street-modeled deceleration to +16%, unreadable lender cash flows, a Q4 EPS miss, a CFO selling, live regulatory exposure, and a KB panel of exactly one undated, crypto-native bullish voice. Our $46 base case (+34%) is not enough margin to override that stack of immaturity at a Risk-8 — the disciplined move is a trigger, not a position.

• Triggers (either one moves this to Buy — Tactical): (1) price into ~$24–28 (≈22× FY27E, near the $25.28 52-wk low) with no thesis damage; or (2) a clean Q2 2026 print (2026-08-10: revenue ≥ ~$202M, no marketplace-mix deterioration) plus a reclaimed 200-DMA (~$39), confirming re-acceleration is worth paying up for.
• Sizing if triggered: speculative sleeve, ≤1% starter — sized for a young, regulation-exposed name where a further −40% is entirely plausible.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score at each print (next 2026-08-10). This verdict is logged as a tracked Synthos call as of 2026-07-06 at $34.41.
• Single biggest risk: a regulatory strike at blockchain-native lending/tokenized securities, or an origination stall — either one hits a 42× trailing multiple with no cushion.

Provenance & disclosures

• Traceability: 5 KB claims, breadth 1 voice (Anthony Pompliano, skill 1.0; two claims relaying founder Mike Cagney), all bullish, all undated in the KB — cited inline by doc id (anthony_pompliano-n9DB2xap9OQ). No bearish or neutral expert voice exists in the KB; the bear case here is fundamentals-built. kb_net_conviction is left null rather than invented from a single voice.
• Data as-of: fundamentals 2026-03-31 (Q1 2026, filed 2026-05-15) · estimates & prices 2026-07-06 (FMP pull) · KB claims undated. Forward figures are analyst consensus (FMP) from 3–5 analysts (FY28: 1), labeled as estimates.
• Data gaps & quirks, stated honestly: no product/geography segment tables in the file; no management-guidance fields; quarterly revenue in the earnings calendar (e.g., $157.6M for the Feb-2026 report) differs from the GAAP income-statement quarters ($223.2M Q4-25) — likely differing revenue definitions; the FMP estimate rows show EBIT above EBITDA (a vendor data quirk); listed beta (−0.21) is not meaningful on eight months of trading; TTM stock-comp ratio (0.5%) conflicts with the FY25 statement ($62.4M ≈ 14% of revenue) — we cite the audited annual figure.
• Earnings-quality caveat: FY25 and Q1-26 net income include tax benefits; TTM operating cash flow is deeply negative on lender working-capital mechanics — underwrite pre-tax earnings power and origination volumes, not headline EPS or OCF alone.
• Expert caveat: single-voice, undated, crypto-native coverage partly relaying the founder — treated as color, not conviction; conviction is scored Low by construction.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").